Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...

FF/VI was administered once daily via the Ellipta inhaler. Patients who were taking a LAMA in addition to ICS/LABA therapy (triple therapy) who were randomised to the FF/VI group were able to ...

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...

Study Aim To describe treatment pathways 5 years prior to initiation of dual bronchodilator therapy (LABA+LAMA) or on triple inhaled therapy (ICS+LABA+LAMA), in single or separate inhalers, in ...

New York State Teachers Retirement System lowered its stake in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.4% ...

It has an inhaled corticosteroid [ICS], a long-acting muscarinic antagonist [LAMA], and a long-acting beta-agonist [LABA] to reduce inflammation and improve breathing. Once again, Trelegy’s ...

In September, enrollment began in a Phase 2 dose-ranging trial supporting a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a LAMA for ... on LABA ICS being added Ohtuvayre.

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.